CN119584986A - 使用Mu阿片类药物受体拮抗剂治疗癌症和其他病症的方法 - Google Patents

使用Mu阿片类药物受体拮抗剂治疗癌症和其他病症的方法 Download PDF

Info

Publication number
CN119584986A
CN119584986A CN202380026567.3A CN202380026567A CN119584986A CN 119584986 A CN119584986 A CN 119584986A CN 202380026567 A CN202380026567 A CN 202380026567A CN 119584986 A CN119584986 A CN 119584986A
Authority
CN
China
Prior art keywords
cancer
mor antagonist
inhibitor
mor
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380026567.3A
Other languages
English (en)
Chinese (zh)
Inventor
洛林·约翰逊
乔纳森·莫斯
大卫·塔戈特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Greasek Moore Co
Original Assignee
Greasek Moore Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Greasek Moore Co filed Critical Greasek Moore Co
Publication of CN119584986A publication Critical patent/CN119584986A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202380026567.3A 2022-03-10 2023-03-10 使用Mu阿片类药物受体拮抗剂治疗癌症和其他病症的方法 Pending CN119584986A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263318465P 2022-03-10 2022-03-10
US63/318,465 2022-03-10
PCT/US2023/064088 WO2023173055A2 (en) 2022-03-10 2023-03-10 Methods of treating cancer and other conditions with a mu opioid receptor antagonist

Publications (1)

Publication Number Publication Date
CN119584986A true CN119584986A (zh) 2025-03-07

Family

ID=87936037

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380026567.3A Pending CN119584986A (zh) 2022-03-10 2023-03-10 使用Mu阿片类药物受体拮抗剂治疗癌症和其他病症的方法

Country Status (10)

Country Link
US (1) US20250186423A1 (https=)
EP (1) EP4489866A4 (https=)
JP (1) JP2025508131A (https=)
KR (1) KR20250004644A (https=)
CN (1) CN119584986A (https=)
AU (1) AU2023231655A1 (https=)
CA (1) CA3253916A1 (https=)
IL (1) IL315501A (https=)
TW (1) TW202400158A (https=)
WO (1) WO2023173055A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
WO2025137697A1 (en) * 2023-12-21 2025-06-26 Glycyx Mor Inc. Methods, systems, and compositions related to use of mu opioid receptor (mor) antagonists
CN121534059A (zh) * 2024-08-09 2026-02-17 盐野义有限公司 一种治疗帕金森综合征或帕金森病的方法和药物组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8524731B2 (en) * 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
ES2714198T3 (es) * 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
JP6686013B2 (ja) * 2014-10-17 2020-04-22 サリックス ファーマスーティカルズ，インコーポレーテッド 腫瘍の進行を減弱させるためのメチルナルトレキソンの使用
EP3490542A4 (en) * 2016-07-26 2020-07-08 Flagship Pioneering Innovations V, Inc. NEUROMODULATION COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATION OF AN ANTI-CANCER RESPONSE
US12053523B2 (en) * 2017-12-13 2024-08-06 North Carolina State University Compositions comprising chemotherapeutic agents and checkpoint inhibitors and methods of use
US11471459B2 (en) * 2018-03-26 2022-10-18 Fondazione Per L'istituto Oncologico Di Ricerca (Ior) Compounds with enhanced anti-tumor effects
US20220125844A1 (en) * 2020-10-23 2022-04-28 The Johns Hopkins University Opioid antagonists for use in patients using chimeric antigen receptor t and natural killer (nk) cell therapy

Also Published As

Publication number Publication date
JP2025508131A (ja) 2025-03-21
TW202400158A (zh) 2024-01-01
EP4489866A2 (en) 2025-01-15
KR20250004644A (ko) 2025-01-08
IL315501A (en) 2024-11-01
WO2023173055A2 (en) 2023-09-14
US20250186423A1 (en) 2025-06-12
AU2023231655A1 (en) 2024-10-17
EP4489866A4 (en) 2026-03-11
CA3253916A1 (en) 2023-09-14
WO2023173055A3 (en) 2023-10-19

Similar Documents

Publication Publication Date Title
CN119584986A (zh) 使用Mu阿片类药物受体拮抗剂治疗癌症和其他病症的方法
JP6905075B2 (ja) 腫瘍の治療または予防のための併用療法
TWI386203B (zh) 治療腦癌或用以降低腦癌細胞對替莫唑胺之抗藥性之醫藥組合物及其應用
CN105705148B (zh) 使用普那布林和紫杉烷的组合的癌症疗法
CA2904671C (en) Treatment of a diastolic cardiac dysfunction with a trpv2 receptor agonist
JP7001599B2 (ja) 急性骨髄性白血病の処置のためのダクチノマイシン組成物および方法
US12121565B2 (en) Methods of treatment of specific cancers with NLRP3 inhibitors and anti-PD1/PD-L1 antibodies
KR20180130589A (ko) 마이크로rna 조성물 및 이의 제조 및 사용 방법
JP2021130704A (ja) Ａｔ２ｒ活性を調節するための組成物および方法
US10632100B2 (en) Application of obacunone in preparation of drug for preventing and treating lung damage and pulmonary fibrosis
US20180263971A1 (en) Combination of topoisomerase-i inhibitors with immunotherapy in the treatment of cancer
WO2019103984A1 (en) Compositions including fatp1, fatp3, fatp4, fatp5, and/or fatp6 inhibitors and uses thereof
US20250186393A1 (en) Treatment of breast cancer with amcenestrant
WO2025060553A1 (zh) 马普替林与ctla4抗体联用在制备抗肿瘤药物中的应用
CN116920100A (zh) 一种治疗肿瘤的药物组合物及其应用
US20210196800A1 (en) Des-acyl ghrelin and analogs as cancer therapies
CN113143922A (zh) Dhc在制备动脉粥样硬化治疗制剂中的应用
KR20230022002A (ko) miR-16-5p 및 소마토스타틴 유사체를 포함하는 종양 예방 또는 치료용 약학적 조성물
KR20160093637A (ko) 종양에 대한 직접적 억제 효과를 갖는 인터페론을 결정하는 방법 및 그의 용도
CN116019810B (zh) FoXO1抑制剂在制备淋巴瘤预防和治疗药物中的应用
JP2026500734A (ja) 医薬組み合わせ、及びその使用
Wang The Role of LIF in Tissue Homeostasis, Disease, and Cancer
Pan et al. Myofibroblast-specific inhibition of ASPP1 alleviates myocardial fibrosis by enhancing p53 degradation
WO2024086533A2 (en) Methods for treating or preventing neuroendocrine tumor formation using cdc7 inhibitors
EP4452275A1 (en) Combination of cisplatin and elimusertib for the treatment of pediatric liver cancers

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination